|
|
Article: PowderMed Manufactures a Vaccine Against H5N1 (Avian Influenza) for Clinical Development.
- Article from:
- Business Wire
- Article date:
- August 1, 2005
CopyrightCOPYRIGHT 2005 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
OXFORD, England -- PowderMed, the immunotherapeutics company focused on the development and manufacture of DNA-based vaccines for viral diseases and cancer, has announced that it has progressed its H5N1 Avian Influenza Vaccine programme into the final stages of preclinical development. PowderMed has produced an H5N1 vaccine by cloning the H5 gene from the current circulating avian flu strain ("the gene cassette") into the company's proprietary DNA vaccine backbone and the vaccine is now ready for development. Manufacturing and toxicology studies are now in progress, and it is anticipated that this vaccine will enter clinical trials by the middle of 2006.
...
Related newspaper, magazine, and journal articles:
|
|
Article: Chiron Spins Powder Injection Technology Into PowderMed ...
BIOWORLD Today;
November 3, 2009 ;
700+ words
... ... continue under the stewardship of PowderMed, with its experienced management ... Partners. Although none of PowderMed's DNA vaccines are in the ... form of Fluvirin, Chiron's flu vaccine. PowderMed has rights to the hepatitis ...
|
|